Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · IEX Real-Time Price · USD
7.90
+0.63 (8.67%)
At close: Jun 7, 2024, 4:00 PM
7.82
-0.08 (-1.01%)
After-hours: Jun 7, 2024, 7:37 PM EDT
Relay Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Relay Therapeutics stock have an average target of 22.8, with a low estimate of 15 and a high estimate of 30. The average target predicts an increase of 188.61% from the current stock price of 7.90.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RLAY stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +153.16% | Jun 7, 2024 |
| Barclays | Barclays | Hold → Buy Upgrades $15 | Hold → Buy | Upgrades | $15 | +89.87% | May 10, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $24 | Buy | Reiterates | $24 | +203.80% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $33 → $25 | Buy | Reiterates | $33 → $25 | +216.46% | May 6, 2024 |
| Stifel | Stifel | Strong Buy Maintains $25 → $30 | Strong Buy | Maintains | $25 → $30 | +279.75% | Feb 22, 2024 |
Financial Forecast
Revenue This Year
10.40M
from 25.55M
Decreased by -59.30%
Revenue Next Year
11.30M
from 10.40M
Increased by 8.67%
EPS This Year
-2.88
from -2.79
EPS Next Year
-2.90
from -2.88
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 12.1M | 69.9M | 82.1M | 97.7M | 424.3M |
| Avg | 10.4M | 11.3M | 23.1M | 55.5M | 194.1M |
| Low | 9.8M | n/a | n/a | 10.8M | 63.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -52.7% | 571.8% | 626.7% | 322.2% | 664.3% |
| Avg | -59.3% | 8.7% | 104.7% | 140.1% | 249.6% |
| Low | -61.6% | - | - | -53.4% | 14.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.87 | -2.55 | -1.97 | -1.61 | -0.08 |
| Avg | -2.88 | -2.90 | -2.67 | -2.35 | -1.44 |
| Low | -2.97 | -3.36 | -3.17 | -3.16 | -2.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.